Enovix Corporation
$750.28M- Market cap
- $732.96M
- Debt
- +$529.37M
- Cash
- −$512.04M
Capital structure 58% equity / 42% debt · EV / Revenue 23.58x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ENVX stock price at premium vs PTCT $3.34 current versus $0.48 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PTCT's multiple
Implied fair value · at ENVX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ENVX FY 2025 (ended Dec 28, 2025) · PTCT FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 58% equity / 42% debt · EV / Revenue 23.58x
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
PTCT carries the larger enterprise value at $4.13B against $750.28M; PTCT trades on the lower EV / Revenue multiple (2.38x vs 23.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Enovix Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.95x
-1.40x
Net debt / EBITDA
Leverage against operating earnings
-0.15x
-2.21x
Cash and equivalents
Liquid reserves on the balance sheet
$512.04M
$1.95B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QuantumScape Corp
ENVX vs QS
Eos Energy Enterprises, Inc.
ENVX vs EOSE
Microvast Holdings, Inc.
ENVX vs MVST
AEHR TEST SYSTEMS
ENVX vs AEHR
VERTEX PHARMACEUTICALS INC / MA
ENVX vs VRTX
Sarepta Therapeutics, Inc.
ENVX vs SRPT
BIOMARIN PHARMACEUTICAL INC
ENVX vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
ENVX vs ALNY
$529.37M
$286.63M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.